How to buy Biomarin Pharmaceutical stock
Learn how to easily invest in Biomarin Pharmaceutical stock.
Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Biomarin Pharmaceutical employs 3,082 staff and has a trailing 12-month revenue of around $2.2 billion.
How to buy Biomarin Pharmaceutical stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BMRN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Biomarin Pharmaceutical stock price (NASDAQ: BMRN)Use our graph to track the performance of BMRN stocks over time.
Biomarin Pharmaceutical shares at a glance
|Latest market close||$86.27|
|52-week range||$80.53 - $117.77|
|50-day moving average||$89.37|
|200-day moving average||$96.88|
|Wall St. target price||$117.18|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.52|
Buy Biomarin Pharmaceutical stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Biomarin Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biomarin Pharmaceutical price performance over time
|1 week (2023-09-15)||-2.14%|
|1 month (2023-08-22)||-4.71%|
|3 months (2023-06-22)||-9.77%|
|6 months (2023-03-18)||N/A|
|1 year (2022-09-22)||1.59%|
|2 years (2021-09-22)||9.16%|
|3 years (2020-09-22)||8.71%|
|5 years (2018-09-21)||97.84|
Is Biomarin Pharmaceutical stock undervalued or overvalued?
Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biomarin Pharmaceutical's P/E ratio
Biomarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 171x. In other words, Biomarin Pharmaceutical shares trade at around 171x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Biomarin Pharmaceutical's PEG ratio
Biomarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6435. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biomarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biomarin Pharmaceutical's EBITDA
Biomarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $194 million.
The EBITDA is a measure of a Biomarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Biomarin Pharmaceutical financials
|Revenue TTM||$2.2 billion|
|Operating margin TTM||4.15%|
|Gross profit TTM||$1.6 billion|
|Return on assets TTM||0.91%|
|Return on equity TTM||2.15%|
|Market Capitalization||$16.7 billion|
TTM: trailing 12 months
Biomarin Pharmaceutical share dividends
We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.
Biomarin Pharmaceutical share price volatility
Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $80.53 up to $117.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.3607. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).
Biomarin Pharmaceutical overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U. S.
Biomarin Pharmaceutical in the news
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
BioMarin's share prices fluctuate following Phase 3 clinical trial results
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
Frequently asked questionsWhat percentage of Biomarin Pharmaceutical is owned by insiders or institutions?
Currently 0.488% of Biomarin Pharmaceutical shares are held by insiders and 97.772% by institutions. How many people work for Biomarin Pharmaceutical?
Latest data suggests 3,082 work at Biomarin Pharmaceutical. When does the fiscal year end for Biomarin Pharmaceutical?
Biomarin Pharmaceutical's fiscal year ends in December. Where is Biomarin Pharmaceutical based?
Biomarin Pharmaceutical's address is: 770 Lindaro Street, San Rafael, CA, United States, 94901 What is Biomarin Pharmaceutical's ISIN number?
Biomarin Pharmaceutical's international securities identification number is: US09061G1013 What is Biomarin Pharmaceutical's CUSIP number?
Biomarin Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 09061G101
More guides on Finder
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Ask an Expert